Guggenheim Reiterates Buy Rating on Twist Bioscience

Guggenheim has reiterated its buy rating for Twist Bioscience Corporation (NasdaqGS: TWST) with a price target of $107. The announcement was made by analyst Subbu Nambi on June 29, 2026. Shares of Twist Bioscience traded near $99.84 on Monday.

Other Institutional Activity in Twist Bioscience

Several institutional investors have adjusted their positions in Twist Bioscience. Artisan Partners Limited Partnership increased its holdings by 537,572 shares, reaching a total of 6,367,777 shares worth about $302.6 million. ARK Investment Management LLC reduced its stake by 1,216,762 shares, ending with 6,342,733 shares valued at approximately $301.4 million. BlackRock, Inc. also trimmed its position by 340,610 shares, holding 5,554,362 shares valued at $263.9 million. EdgePoint Investment Group Inc. made a modest increase of 4,530 shares, bringing its total to 5,382,521 shares worth $255.8 million. Meanwhile, William Blair Investment Management, LLC cut its holdings by 684,711 shares, leaving it with 5,269,718 shares valued at around $250.4 million.

Twist Bioscience Corporation Stock Down 27.2%

On Monday, shares of Twist Bioscience traded near $99.84. The company, which operates in the diagnostics and research industry within the healthcare sector, has a market capitalization of approximately $6.22 billion. Twist Bioscience's forward P/E ratio is not meaningful due to its lack of profitability, as indicated by a negative EPS of -1.32. The stock's beta is 2.214, suggesting higher volatility compared to the market. It has a 52-week low of $23.30 and a high of $104.23, with a 50-day moving average of $66.38 and a 200-day moving average of $44.83.

Recent Earnings

Twist Bioscience reported revenue of $409.5 million, reflecting a growth rate of 19.3%. Despite this growth, the company posted a net margin of -19.8%, and a return on equity of -18.2%. The next earnings report is expected on August 3, 2026.

Insider Buying and Selling at Twist Bioscience Corporation

Recent insider activity at Twist Bioscience includes planned sales by CEO Emily Leproust, who sold 18,880 shares at $95 on June 25, 2026. Senior Vice President Dennis Cho sold 14,205 shares at $89.75 on June 24, 2026, also as part of a planned transaction. On June 22, 2026, Leproust and Cho sold 1,688 and 346 shares, respectively, at $87.32. Paula Green, SVP of Human Resources, sold 291 shares at the same price on June 22, 2026.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim maintained its buy rating for Twist Bioscience with a $107 price target. Barclays also maintained a buy rating with a $95 target on June 24, 2026. Earlier, TD Cowen and Canaccord Genuity maintained and initiated buy ratings with targets of $89 and $90, respectively, on June 15, 2026. Piper Sandler initiated a buy rating on June 11, 2026, with an $85 target.

About Twist Bioscience

Twist Bioscience Corporation, headquartered in South San Francisco, California, specializes in manufacturing synthetic DNA-based products. The company serves a variety of sectors, including therapeutics, diagnostics, and agricultural research. Led by CEO Dr. Emily Marine Leproust, Twist Bioscience employs 979 people and focuses on innovative applications like gene editing and data storage in DNA.

Bottom Line

Twist Bioscience continues to attract attention from institutional investors and analysts alike. Guggenheim's reiterated buy rating and $107 price target highlight confidence in the company's potential. Investors should note that 13F filings and analyst ratings are backward-looking and may not reflect current positions or recommendations.